The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | Prognostic markers and MRD in CLL
Robin Foà
• 25 Oct 2018
Speaking from the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, held in Barcelona, Spain, Robin Foà, MD, of the Sapienza University of Rome, Rome, Italy, discusses the key prognostic markers and measurable residual disease in chronic lymphocytic leukemia.
